Historical Review of Carcinoma wsr to Aetiology

Authors

  • Gyanendra kumar Gupta Professor & Head, Department of Kriya Sharir, SRS Ayurvedic Medical College, Agra, Uttar Pradesh, India
  • Gagan Devi Assistant Professor, Department of Rachna Sharir, SRS Ayurvedic Medical College, Agra, Uttar Pradesh, India

Keywords:

Cancer, Cancer Survivor, Radiation, Tumour and Malignant

Abstract

No one would choose to be diagnosed with cancer. It is perhaps the most dreaded disease of mankind. Regardless of the stage of disease, each individual is a cancer survivor. From the moment of diagnosis and for the rest of his life, that person is engaged in the pursuit of life. Treatment of cancer ranges from the use of powerful chemicals, bursts of radiation to complete removal of tumour and surrounding tissue. Each treatment type brings a certain level of risk, pain and disability to the patient, but malignant cells when left untreated inevitably choke off vital organs and circulation. So in this article an attempt is made to highlight aetiology of Ca. So that we can aware of its cause and help in prevention of carcinoma.

References

Abeloff: Clinical Oncology, 3rd ed. Churchill Livingston, 2004. Pp 408413.

Goodman LS, Wintrobe MM, et al. Nitrogen mustard therapy. Use of methyl-bis (betachloroethyl) amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. J Am Med Assoc.1946 Sep 21;132:126-32.

Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg.1963 May;105:574-8.

Gilman A. The biological actions and therapeutic applications of the Bchloroethyl amines and sulfides. Science.1946 Apr 5;103(2675):409-36.

Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic antagonist, 4aminopteroylglutamic acid (aminopterin). N Engl J Med.1948 Jun 3;238(23):787-93.

Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med.1976 Feb 19;294(8):405-10.

Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med 1958 Jul 10;259(2):66-74.

Jaffe N, Link MP, Cohen D, Traggis D, et al. High-dose methotrexate in osteogenic sarcoma. Natl Cancer Inst Monogr.1981 Apr;(56):201-6.

Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem.2002 Aug 30;277(35):32214-9.

O'Brien SG, Guilhot F, et al. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med.2003 Mar 13;348(11):994-1004.

Downloads

Published

2021-10-05

Issue

Vol. 10 No. 2 (2021)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.